Dr. Raya Saba, MD
Hematology & Oncology (Hematology & Oncology Physician)
10050 Kennerly Rd Ste 2400
Saint Louis, MO 63128
Who else practices at this address →
St. Louis County includes dental (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 15
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 171
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MO license 2016015284 -
Hospitalist Physician
MO license 2016015284
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mercy Hospital St Louis Saint Louis, MO
- St Lukes Hospital of Kansas City Kansas City, MO
- Mercy Hospital South Saint Louis, MO
Medical groups
- Mercy Clinic Oncology LLC (33 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 171
- Services billed
- 378
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| New patient office or other outpatient visit, 45-59 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Saint Louis, MO | 42 |
| Revlimid (lenalidomide) | 40 |
| Xarelto (rivaroxaban) Other prescribers in Saint Louis, MO | 31 |
| Hydroxyurea Other prescribers in Saint Louis, MO | 29 |
| Eliquis (apixaban) Other prescribers in Saint Louis, MO | 25 |
| Ondansetron Hcl Other prescribers in Saint Louis, MO | 21 |
| Jakafi (ruxolitinib phosphate) | 18 |
| Warfarin Sodium Other prescribers in Saint Louis, MO | 16 |
| Brukinsa (zanubrutinib) | 16 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Saint Louis, MO | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 24 companies reported 28 payments worth $2,934 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $2,370 |
|---|---|
| Daiichi Sankyo Inc. | $57.24 |
| Merck Sharp & Dohme LLC | $53.18 |
| Eisai Inc. | $48.32 |
| Genentech USA, Inc. | $30.61 |
| Regeneron Healthcare Solutions, Inc. | $30.36 |
| E.r. Squibb & Sons, L.l.c. | $25.78 |
| AbbVie Inc. | $24.76 |
| Consulting Fee | $2,345 |
|---|---|
| Food and Beverage | $589 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Nov 17, 2025 | Consulting Fee CALQUENCE · Oncology | $2,345 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $21,700 in research payments for these studies, mostly to the institutions running them.
- M24-287 - A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreate…
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.